STERIS (NYSE:STE) Price Target Lowered to $270.00 at UBS Group

07 Aug 2026, 19:42 by Renee Jackson · The Cerbat Gem

STERIS (NYSE:STE – Get Free Report) had its price objective cut by analysts at UBS Group from $275.00 to $270.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. UBS Group’s target price indicates a potential upside of 13.59% from the company’s previous close.

STE has been the subject of a number of other reports. KeyCorp lowered their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, Wall Street Zen cut STERIS from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $277.25.

Read Our Latest Research Report on STE

STERIS Price Performance

STERIS stock traded up $5.92 during midday trading on Friday, reaching $237.70. The company’s stock had a trading volume of 804,021 shares, compared to its average volume of 803,791. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The stock has a market cap of $23.17 billion, a PE ratio of 29.06 and a beta of 0.91. STERIS has a 52 week low of $195.14 and a 52 week high of $269.44. The business has a 50-day moving average price of $214.35 and a 200-day moving average price of $225.40.

STERIS (NYSE:STE – Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.39%. During the same period in the previous year, the company earned $2.34 earnings per share. STERIS’s revenue for the quarter was up 7.3% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. On average, sell-side analysts predict that STERIS will post 11.17 EPS for the current year.

Insider Activity at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 3,054 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $214.64, for a total transaction of $655,510.56. Following the sale, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at $13,956,107.44. The trade was a 4.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP John Adam Zangerle sold 1,419 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the transaction, the vice president owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,328 shares of company stock worth $1,554,051 in the last quarter. 1.12% of the stock is owned by insiders.

Institutional Trading of STERIS

Institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp grew its position in shares of STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after buying an additional 349 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of STERIS by 32.3% during the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after acquiring an additional 59,264 shares during the last quarter. Empowered Funds LLC raised its position in shares of STERIS by 16.1% during the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after acquiring an additional 319 shares during the last quarter. Woodline Partners LP lifted its stake in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock worth $1,881,000 after acquiring an additional 2,372 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after acquiring an additional 5,803 shares during the period. Institutional investors own 94.69% of the company’s stock.

Trending Headlines about STERIS

Here are the key news stories impacting STERIS this week:

Positive Sentiment: Piper Sandler raised its price target to $275 from $270 while reaffirming an “overweight” rating. The revised target implies roughly 16% potential upside from the referenced share price, signaling continued confidence in STERIS’s earnings growth and medical-equipment demand. Benzinga analyst rating report
Positive Sentiment: Fiscal first-quarter adjusted EPS came in at $2.59, ahead of the approximately $2.49 consensus estimate, while revenue rose 7.3% year over year to $1.49 billion. Growth was broad-based: Healthcare revenue increased 8%, Applied Sterilization Technologies rose 6% and Life Sciences advanced 9%. STERIS fiscal 2027 first-quarter results
Positive Sentiment: STERIS plans to invest approximately $600 million in a North Carolina manufacturing hub expected to create about 335 jobs. The project should expand production capacity and support the company’s formulated-chemistries business over the longer term. STERIS North Carolina manufacturing investment
Neutral Sentiment: Fiscal 2027 guidance was maintained broadly in line with expectations. Adjusted EPS is projected at approximately $11.00–$11.30 and revenue at about $6.4 billion, consistent with expected 7%–8% revenue growth. The company increased capital-expenditure guidance to roughly $450 million and expects free cash flow of about $800 million.
Negative Sentiment: Revenue was described as modestly below some estimates despite the earnings beat, and operating cash flow declined year over year. STERIS also expects $55 million–$70 million in pretax restructuring charges tied to the North Carolina center, creating near-term cost and execution risks. STERIS earnings analysis

About STERIS

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.